Doxofylline

Doxofylline
Clinical data
AHFS/Drugs.comInternational Drug Names
Routes of
administration		By mouth
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
  • 7-(1,3-Dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.067.468 Edit this at Wikidata
Chemical and physical data
FormulaC11H14N4O4
Molar mass266.257 g·mol−1
3D model (JSmol)
  • CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3
  • InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3
  • Key:HWXIGFIVGWUZAO-UHFFFAOYSA-N
  (verify)

Doxofylline (also known as doxophylline) is a phosphodiesterase inhibiting bronchodilator used in the treatment of chronic respiratory diseases such as asthma[1] and COPD.[2] Like theophylline, it is a xanthine derivative.[3][4]

  1. ^ Cirillo R, Barone D, Franzone JS (1988). "Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors". Archives Internationales de Pharmacodynamie et de Therapie. 295: 221–37. PMID 3245738.
  2. ^ Cazzola M, Calzetta L, Rogliani P, Page C, Matera MG (August 2018). "Impact of doxofylline in COPD: A pairwise meta-analysis" (PDF). Pulmonary Pharmacology & Therapeutics. 51: 1–9. doi:10.1016/j.pupt.2018.04.010. PMID 29705620.
  3. ^ Dini FL, Cogo R (2001). "Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects". Current Medical Research and Opinion. 16 (4): 258–68. doi:10.1185/030079901750120196. PMID 11268710.
  4. ^ Poggi R, Brandolese R, Bernasconi M, Manzin E, Rossi A (October 1989). "Doxofylline and respiratory mechanics. Short-term effects in mechanically ventilated patients with airflow obstruction and respiratory failure". Chest. 96 (4): 772–8. doi:10.1378/chest.96.4.772. PMID 2791671. Archived from the original on 2013-04-14.